Rani Therapeutics Holdings, Inc.: management transactions · United States · SEC (Form 4)

About Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. is a U.S.-based biotechnology company listed on the Nasdaq market (United States) and focused on oral delivery of biologics and drugs that are traditionally administered by injection or infusion. The company’s core thesis is that many high-value therapies could be transformed into patient-friendly oral treatments through its proprietary RaniPill platform, an ingestible capsule designed to deploy a precise dose in the small intestine. In equity terms, this places Rani in the clinical-stage, platform-biotech category: it is not yet a mature commercial drug company, but rather a developer of enabling technology with optionality across multiple therapeutic areas. ([ir.ranitherapeutics.com](https://ir.ranitherapeutics.com/?utm_source=openai)) Rani Therapeutics was built around a differentiated drug-delivery concept and an extensive intellectual-property portfolio. Its headquarters are in San Jose, California, anchoring the company in one of the most established biotechnology clusters in the United States. The firm’s development strategy is to prove that the RaniPill can reliably deliver complex biologics orally, potentially replacing subcutaneous injections and improving adherence, convenience, and patient experience. The company’s investor materials describe several preclinical and clinical studies supporting the platform’s safety, tolerability, and bioavailability profile. ([ir.ranitherapeutics.com](https://ir.ranitherapeutics.com/?utm_source=openai)) Operationally, Rani’s business lines center on platform development, preclinical validation, clinical advancement, and strategic partnering. Rather than depending on a single asset, the company is trying to establish the RaniPill as a repeatable delivery technology for multiple molecules. Recent disclosures show a growing focus on metabolic disease and other biologics-heavy categories. In March 2026, Rani reported preclinical data showing successful oral delivery of semaglutide and preclinical bioequivalence data for RT-114, a bispecific GLP-1/GLP-2 dual agonist. It also initiated a Phase 1 study of RT-114 for obesity in collaboration with ProGen. ([nasdaq.com](https://www.nasdaq.com/press-release/rani-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results?utm_source=openai)) From a competitive standpoint, Rani operates in a demanding segment where success depends on clinical proof, manufacturability, regulatory execution, and the ability to attract pharmaceutical partners. Its main competitive edge is the potential to convert injectable biologics into oral medicines, a proposition that could be highly disruptive if replicated at scale. That said, the company remains exposed to the usual risks of clinical-stage biotech: execution risk, regulatory uncertainty, and the need for continued capital access. In November 2025, Rani announced a collaboration potentially worth up to $1.085 billion with Chugai Pharmaceutical and completed a $60.3 million oversubscribed private placement. The company also said its cash runway was expected to extend into 2028, a meaningful development for a precommercial biotech. ([nasdaq.com](https://www.nasdaq.com/press-release/rani-therapeutics-reports-third-quarter-2025-financial-results-provides-corporate?utm_source=openai)) For international investors, Rani Therapeutics is best viewed as a high-risk, high-upside platform story within healthcare and pharmaceuticals. The key monitoring points are clinical readouts, partner momentum, and the company’s ability to translate its technology into a broader pipeline and ultimately commercial value. Its Nasdaq listing and U.S. headquarters are central reference points, but the investment case will ultimately depend on whether the RaniPill can become a scalable delivery standard for biologics. ([nasdaq.com](https://www.nasdaq.com/press-release/rani-therapeutics-reports-third-quarter-2025-financial-results-provides-corporate?utm_source=openai))